MARKET

MBRX

MBRX

Moleculin Biotec
NASDAQ
8.06
-0.04
-0.49%
After Hours: 8.06 0 0.00% 16:10 11/12 EST
OPEN
8.77
PREV CLOSE
8.10
HIGH
8.90
LOW
7.90
VOLUME
41.77K
TURNOVER
--
52 WEEK HIGH
253.05
52 WEEK LOW
3.228
MARKET CAP
8.46M
P/E (TTM)
-0.0267
1D
5D
1M
3M
1Y
5Y
1D
Moleculin Biotech Announces Australian Patent for Annamycin Formulation
TipRanks · 9h ago
Moleculin granted Australian patent covering preliposomal Annamycin lyophilizate
TipRanks · 10h ago
Moleculin Biotech And University Of Texas Receive Australian Patent Covering The Preparation Of Preliposomal Annamycin Lyophilizate
Benzinga · 11h ago
Moleculin Reports Annamycin Combination Data in Pancreatic Cancer
TipRanks · 2d ago
Moleculin Biotech announces new preclinical data on Annamycin combo
TipRanks · 2d ago
Moleculin Biotech Reports Preclinical Data Showing Annamycin Plus PD-1 Blockade Extends Survival in Pancreatic Cancer Models
Benzinga · 2d ago
Weekly Report: what happened at MBRX last week (1102-1106)?
Weekly Report · 3d ago
Moleculin Biotech, Inc. Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
NASDAQ · 11/05 00:21
More
About MBRX
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

Webull offers Moleculin Biotech Inc stock information, including NASDAQ: MBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MBRX stock methods without spending real money on the virtual paper trading platform.